Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05845476 · ClinicalTrials.gov registry record
Sexual Orientation and Gender Identity (SOGI) Data Collection Program Implementation and Evaluation
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 54
- Enrollment target
NCT05845476: Completed study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT05845476 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05845476 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
Sexual and gender minority (SGM) individuals experience significant cancer-related health disparities across the cancer continuum. The overall goal of this proposal is to assess multi-level barriers associated with sexual orientation and gender identity (SOGI) data collection in the health record as well as implementation factors including feasibility, acceptability, and data completeness. The results of this study will make a significant impact by making SOGI data available for research, addressing barriers to SOGI data collection in a large comprehensive cancer center, and informing compassionate cancer care for SGM people.
Primary Outcome
This variable is observed from the electronic health record (EHR) and reported in aggregate form. The investigators will record and analyze the count (number of patients with sexual orientation documented), percent of patient records containing this documentation out of the total number of patient records, and completeness of variable fields (count and percent).
Interventions
- OTHER Patient SOGI Self-Report
- OTHER SOGI Resource for Clinical Care Education (SORCE)
- OTHER Cancer Center Care Environment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2024-03-14 |
What the finished NCT05845476 record still lists
NCT05845476 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Patient SOGI Self-Report is the first listed.
NCT05845476 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05845476 about?
NCT05845476 is a clinical study titled "Sexual Orientation and Gender Identity (SOGI) Data Collection Program Implementation and Evaluation". Sexual and gender minority (SGM) individuals experience significant cancer-related health disparities across the cancer continuum. The overall goal of this proposal is to assess multi-level barriers associated with sexual orientation and gender identity (SOGI) data collection in the health record as...
What is the current status of trial NCT05845476?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2023-03-14. Estimated completion is 2024-03-14.
What interventions are being tested in trial NCT05845476?
The interventions under investigation include: Patient SOGI Self-Report (OTHER), SOGI Resource for Clinical Care Education (SORCE) (OTHER), Cancer Center Care Environment (OTHER).
Who is sponsoring clinical trial NCT05845476?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI